A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

June 20, 2026

Study Completion Date

June 25, 2026

Conditions

Head and Neck CancerSquamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Pembrolizumab

200mg, every three weeks, iv, x 1 year

DRUG

Placebo

iv, every three weeks, x 1 year

Trial Locations (4)

University of Pennsylvania, Philadelphia

Emory University Winship Cancer Institute, Atlanta

Rush University Medical Center, Chicago

University of Chicago Medical Center, Chicago

All Listed Sponsors

lead

University of Chicago

OTHER